---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-113593"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:29:33.945818+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cellectar to release top-line WM pivotal data at JP Morgan Conference week of Jan 8, 2024; raises up to $102.9M via PIPE

## Summary
- Top-line data from Waldenstrom's macroglobulinemia pivotal trial to be released week of Jan 8, 2024 at JP Morgan Healthcare Conference.
- Closed PIPE with up to $102.9M gross proceeds (milestone-based); initial $24.5M at $1.82/share; led by Rosalind Advisors.
- Received EMA PRIME designation for iopofosine I 131 in WM after two or more prior treatments.
- Cash of $19.0M at Sep 30; net $22.2M from PIPE; believes funded into Q2 2024.
- Q3 R&D expense $7.3M (up from $5.4M YoY); G&A $2.1M (down from $2.4M).

## SEC filing metadata
- accession: 0001104659-23-113593
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/0001104659-23-113593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/tm2329674d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-113593
- JSON: https://secwatch.observer/filing/0001104659-23-113593.json
- Plain text: https://secwatch.observer/filing/0001104659-23-113593.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported preliminary financial results for three months ended September 30, 2023.
  - Period: three months ended September 30, 2023
  - Result: preliminary results
  source text: On November 2, 2023, we issued a press release announcing preliminary financial results for the three months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/0001104659-23-113593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.